Riskpilot← Back to searchSign inGet full accessXGX Pharma ApS
APSActiveCVR 32289290Frederiksgade 11, st. thWholesale of pharmaceutical and medical goods · NACE 4646Est. 20094 employees
Revenue 2024
DKK 16M
+98% vs 2023
EBITDA margin
54.7%
+202% vs 2023
Equity ratio
48.0%
Financial strength
Net profit 2024
DKK 4,5M
+866% vs 2023
| Revenue | DKK 16M | +98% |
| EBITDA | DKK 8,8M | +202% |
| Net profit | DKK 4,5M | +866% |
| Total assets | DKK 39M | +32% |
| Equity | DKK 18,7M | +31% |
| Employees | 4 | — |
Legal name
XGX Pharma ApS
CVR number
32289290
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14. juli 2009
Share capital
DKK 400.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren i forening med ét bestyrelsesmedlem
Company purpose
Selskabets formål er at drive virksomhed med fremstilling, markedsføring og distribution af medicinske produkter samt at udøve enhver aktivitet, der efter ledelsens skøn er forbundet hermed.
Address
Frederiksgade 11, st. th
Phone
+4570276627
Email
msa@vitalpharmanordic.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84 | 145 | — | -33 | 307 | 104 | 1.575 | 11.717 | 15.226 | 14.515 | 2.918 | 8.101 | 16.034 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -1.234 | -3.136 | -4.004 | -5.008 | -4.420 | -5.200 | -7.263 |
| EBITDA | 84 | 145 | -1 | -33 | 307 | -146 | 341 | 8.581 | 11.221 | 9.507 | -1.502 | 2.900 | 8.771 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -128 | -330 | -355 | -434 | -788 | -1.424 | -2.234 |
| EBIT | 84 | 145 | -1 | -33 | 307 | -146 | 213 | 8.251 | 10.866 | 9.073 | -2.290 | 1.476 | 6.537 |
| Net financials | -13 | -0 | -4 | -2 | -27 | -43 | -187 | 1.954 | -2.662 | -141 | -391 | -868 | -916 |
| Profit before tax | 96 | 145 | -5 | -35 | 280 | -189 | 27 | 10.199 | 8.204 | 8.932 | -2.681 | 624 | 5.673 |
| Tax | -0 | -0 | 9 | -0 | 9 | -0 | -0 | -0 | -0 | -0 | -839 | 163 | 1.220 |
| Net profit | 96 | 145 | -14 | -35 | 272 | -189 | 27 | 8.357 | 6.004 | 7.249 | -1.843 | 461 | 4.453 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 66 | 14 | 466 | 900 | 877 | 1.346 | 3.487 | 18.776 | 24.938 | 21.257 | 27.640 | 29.601 | 39.006 |
| Equity | 14 | 130 | -145 | -180 | 92 | 32 | 59 | 11.416 | 12.920 | 13.169 | 13.799 | 14.260 | 18.713 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 1.500 | 1.768 | 1.857 | 1.365 | 7.649 | 5.873 | 3.953 |
| Short-term debt | -52 | -145 | 611 | 1.080 | 785 | 1.313 | 1.928 | 4.630 | 8.716 | 4.215 | 4.522 | 7.636 | 13.288 |
| Total debt | -52 | -145 | 611 | 1.080 | 785 | 1.313 | 3.428 | 6.398 | 10.573 | 5.580 | 12.171 | 13.509 | 17.241 |
EBITDA margin
54.7%
This company
15.8%
Market median
+246% vs market
20122024
Equity ratio
48.0%
This company
38.2%
Market median
+26% vs market
20122024
Return on equity
23.8%
This company
18.4%
Market median
+29% vs market
20122024
Net profit margin
27.8%
This company
8.1%
Market median
+243% vs market
20122024
Asset turnover
0.41×
This company
1.12×
Market median
-63% vs market
20122024
Debt / equity
1.08×
This company
0.62×
Market median
-74% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JS Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2018 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2025 | |
| Individual | 50.0% | 50.0% | 2016 | |
JCNS Holding ApS | Company | 20.0% | 20.0% | 2024 |
E CONSULT ApS | Company | 5.0% | 5.0% | 2022 |
Schøier Holding ApS | Company | 33.3% | 33.3% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
XGX Pharma ApS 
Frederiksstaden Pharma ApSBoard members of XGX Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jens-Nikolaj Schøier | Chief Executive Officer | 0 companies |
| Rolf Eckersberg | Chairman | 0 companies |
| Johan Frödin | Board of Directors | 0 companies |
| Lars Karlsmose | Board of Directors | 0 companies |
| Per Ludvigsen | Chairman | 0 companies |
| Mohammad Sohail Asghar | Chairman | 0 companies |
| Per Anders Larnholt | Chairman | 0 companies |